Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0117)
| Name |
Sodium hydrosulfide
|
||||
|---|---|---|---|---|---|
| Synonyms |
SODIUM HYDROSULFIDE; Sodium bisulfide; 16721-80-5; Sodium sulfhydrate; Sodium hydrogen sulfide; Sodium sulfide (Na(SH)); Sodium mercaptan; Sodium mercaptide; NaHS; Sodium hydrosulphide; sodium sulfanide; Sodium Hydrogensulfide; sodium;sulfanide; Hydrogen sodium sulfide; Sodium sulfide (Na(HS)); Sodium hydrosulfide (Na(HS)); Sodium hydrogen sulfide (NaHS); NA2922; FWU2KQ177W; CHEMBL1644699; NSC-158264; Hidrosulfuro sodics; HNaS; Hidrosulfuro sodics [Spanish]; HSDB 5165; Hydrogenosulfure de sodium [French]; EINECS 240-778-0; Hydrogenosulfure de sodium; UN2318; UN2949; UNII-FWU2KQ177W; NSC 158264; AI3-14915; sodiumhydrogensulfide; sodium hydro-sulfide; MFCD00011124; SODIUM BISULPHIDE; EC 240-778-0; SODIUM BISULFIDE [MI]; GTPL6278; DTXSID3029738; HYHCSLBZRBJJCH-UHFFFAOYSA-M; Sodium hydrogen sulfide, anhydrous; SODIUM HYDROSULFIDE [HSDB]; NSC158264; AKOS015915184; FT-0651301; A810831; Q414203; J-013607; Sodium hydrosulfide, with <25% water of crystallization; Sodium hydrosulfide, with not <25% water of crystallization; Sodium hydrosulfide, with not <25% water of crystallization [UN2949] [Corrosive]; 115694-77-4; Sodium hydrosulfide, with <25% water of crystallization [UN2318] [Spontaneously combustible]
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
HNaS
|
||||
| IUPAC Name |
sodium;sulfanide
|
||||
| Canonical SMILES |
[Na+].[SH-]
|
||||
| InChI |
InChI=1S/Na.H2S/h;1H2/q+1;/p-1
|
||||
| InChIKey |
HYHCSLBZRBJJCH-UHFFFAOYSA-M
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Suppressor | ||||
| Responsed Disease | Depressive disorder | ICD-11: 6A70 | |||
| Responsed Regulator | Cystathionine beta-synthase (CBS) | Suppressor | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| Cell proliferation | |||||
| In Vitro Model | BV-2 cells | Normal | Mus musculus | CVCL_0182 | |
| In Vivo Model |
Adult male 22-24 g C57BL/6J mice were purchased from the Vital River Laboratory Animal Technology Co., Ltd. Mice were randomly divided into four groups, the control group (CON group, n = 8), diabetes mellitus group (DM group, n = 8), DM + sodium hydrosulfide (DM + 5.6 mg/kg NaHS, n = 8) group, and CON + sodium hydrosulfide (CON + 5.6 mg/kg NaHS, n = 8) group. In this experiment, mice have received daily intraperitoneally injection of NaHS during the last 4 weeks. Then, all mice were tested by the open field test (OFT), elevated plus maze test (EPM test), forced swimming test (FST), and tail suspension test (TST).
Click to Show/Hide
|
||||
| Response regulation | Sodium hydrosulfide (NaHS) ameliorated the ferroptosis via increasing the protein expressions of SLC7A11, glutathione peroxidase 4 (GPX4), and cystathionine -synthase (CBS), reducing the pro-inflammatory cytokines, decreasing the levels of Fe2+, MDA, ROS, and lipid ROS. In conclusion, NaHS did alleviate anxiety and depression. | ||||